Potassium chloride

Selected ER tablets, ER capsules, and oral solution treat or prevent hypokalemia, with or without metabolic alkalosis, when potassium-rich diet or reduction of a causative diuretic is inadequate. Establish the deficit and its cause rather than treating an isolated result without clinical review.

The selected concentrate treats potassium deficiency when oral replacement is not feasible. The selected Baxter highly concentrated ready-to-use bags are for patients needing supplementation or maintenance who cannot accommodate additional fluid volumes; they require continuous cardiac monitoring and frequent potassium and acid-base testing.

This profile distinguishes Klor-Con 8/10 mEq wax-matrix tablets, selected generic microencapsulated capsules, oral solution, and two IV product types. The public Micro-K label is historical and is discussed only to show its distinct instructions; current brand availability is not verified. Other ER tablets, mixed-electrolyte bags, and feeding-tube protocols are outside this reference.

Selected solution, birth–16 years: initial treatment 2–4 mEq/kg/day in divided doses; each dose must not exceed 1 mEq/kg or 40 mEq, whichever is lower, and total must not exceed 100 mEq/day. Maintenance typically 1 mEq/kg/day, not exceeding 3 mEq/kg/day. Selected capsules, birth–16 years: initial 2–4 mEq/kg/day divided; each dose ≤1 mEq/kg or 20 mEq, whichever is lower; prevention typically 1 mEq/kg/day. Klor-Con wax-matrix tablet pediatric safety/effectiveness is not established. These distinct product limits are not interchangeable.

Take solids with meals and a full glass of liquid. Swallow Klor-Con wax-matrix tablets whole; do not crush, chew, or suck. Selected capsules may be opened onto a spoonful of cool soft food, swallowed immediately without chewing, followed by a glass of water or juice; do not store the mixture or use hot food. Dilute each oral-solution dose with at least 4 fl oz of cold water and take with or immediately after meals. No selected label here establishes administration through an enteral tube; obtain a product-specific pharmacy protocol.

Oral 10% solution contains 20 mEq/15 mL; 20% contains 40 mEq/15 mL. Verify the prescribed mEq before measuring volume. The historical Micro-K label limits a single dose to 20 mEq, unlike the selected current generic capsule’s 40 mEq adult limit; it must not be used to infer a universal capsule regimen.

Hospira concentrate is 2 mEq/mL and must be diluted and thoroughly mixed; when potassium is above 2.5 mEq/L, its label limits infusion to 10 mEq/hour, at no more than 40 mEq/L, with up to 200 mEq/24 hours. Baxter ready-to-use bags contain 100, 200, or 400 mEq/L: use a calibrated infusion device; 400 mEq/L requires central IV access, and central access is recommended whenever possible for all selected strengths. Verify catheter placement; use continuous cardiac monitoring and frequent potassium/acid-base testing. Its usual rate is ≤10 mEq/hour and ≤200 mEq/24 hours when potassium is above 2.5 mEq/L.

The selected oral labels direct IV treatment when potassium is below 2.5 mEq/L. IV labels describe rates up to 40 mEq/hour and 400 mEq/24 hours only for urgent, profound hypokalemia below 2.0 mEq/L with ECG changes and/or muscle paralysis, under continuous ECG and frequent serum-potassium monitoring. These are exceptional supervised limits, never a routine replacement order; concentration, access, rate, serial labs, and institutional safeguards must all be confirmed. No universal regimen for the 2.0–2.5 mEq/L interval or pediatric IV protocol is supplied here.

Klor-Con tablets and selected generic capsules contraindicate amiloride or triamterene; the selected oral solution contraindicates concomitant potassium-sparing diuretics more broadly. Do not administer potassium to treat a patient who is already hyperkalemic. Hospira concentrate specifically contraindicates hyperkalemia, renal failure, and potassium-retention conditions. Baxter ready-to-use bags contraindicate hyperkalemia or product hypersensitivity; severe renal impairment requires extreme caution, if use is contemplated at all.

The selected current oral and IV labels do not contain a formally coded boxed warning. This does not reduce the danger: the concentrate prominently warns that undiluted IV administration can be instantly fatal, and the ready-to-use label mandates controlled infusion and monitoring.

Oral therapy can cause nausea, vomiting, abdominal discomfort, gas, and diarrhea. Serious events include hyperkalemia and solid-product GI injury. IV reactions include arrhythmia or arrest, infusion-site pain, phlebitis or thrombosis, extravasation injury, electrolyte disturbances and fluid overload; hypersensitivity is reported with the selected ready-to-use product. Postmarketing reports do not provide reliable frequencies.

Avoid the product-specific contraindicated combinations described above. Amiloride/triamterene are contraindicated with the selected tablets/capsules; the selected solution contraindicates potassium-sparing diuretics. Spironolactone/eplerenone are also potassium-retaining RAAS therapies and require careful product-specific review, rather than assuming one oral label’s wording applies to all.

ACE inhibitors, ARBs, aliskiren, and other potassium-retaining RAAS therapies increase hyperkalemia risk; NSAIDs can also retain potassium. Monitor potassium closely when an oral combination is necessary. The selected Baxter IV label advises avoiding potassium-raising products including ACE inhibitors, ARBs, potassium-sparing diuretics, cyclosporine, and tacrolimus; if unavoidable, monitor closely.

Diuretics and some antiepileptic/psychotropic medicines can increase IV-fluid-associated hyponatremia risk. Assess sodium and fluid balance as well as potassium. Patients receiving digitalis need close electrolyte and ECG assessment; rapid changes during treatment of potassium intoxication can provoke digitalis toxicity.

For oral products, start at the lower end of the dose range in renal impairment, monitor potassium frequently, and assess renal function; no universal creatinine-clearance dosing table is established. Cirrhosis can increase the potassium response to an oral load, so start low and monitor. The IV concentrate contraindicates renal failure; the ready-to-use product requires extreme caution, if at all, in severe renal impairment.

Pediatric regimens above apply only to selected oral capsules/solution. Klor-Con wax-matrix tablet pediatric use is not established. The selected highly concentrated Baxter ready-to-use bags should not be used in children according to their label; no pediatric IV regimen is extrapolated from adult rates. Older patients often need lower initial oral dosing and closer renal/electrolyte surveillance.

Oral-label human pregnancy data are limited and animal studies were not conducted; supplementation that does not cause hyperkalemia is not expected to cause fetal harm. Normal maternal supplementation is not expected to materially change milk potassium. The selected IV labels have more cautious pregnancy/lactation language because adequate studies are absent; use requires a patient-specific benefit-risk assessment.

Potassium is the main intracellular cation and supports nerve conduction, muscle contraction, and cellular metabolism. Chloride replacement is appropriate in many chloride-depletion states. Assessment must include the cause of loss and acid-base balance; replacement is individualized rather than based on a fixed pharmacologic half-life.

Oral ER products distribute potassium release over time, while solution has a faster initial absorption pattern. Selected microencapsulated capsules release over approximately 8–10 hours. The kidneys are the principal route of potassium elimination, making renal impairment a key toxicity determinant. Serum potassium can be normal despite a total-body deficit, or rise rapidly during redistribution.

The selected Klor-Con tablet’s emptied wax matrix may be seen in stool. This is an expected delivery-system remnant and does not mean the prescribed dose should be repeated. Do not extrapolate this observation into permission to crush the tablet.

Check serum potassium, renal function, acid-base and fluid status before and during replacement; assess magnesium and other electrolytes when relevant. The oral solution label calls for daily or more frequent potassium checks during treatment until normal and less frequent surveillance during stable maintenance. Unstable illness, renal impairment, interacting drugs, or IV replacement require more intensive assessment. Use ECG monitoring as indicated; selected concentrated ready-to-use IV bags require continuous cardiac monitoring and frequent labs.

Confirm mEq, product concentration, and measured volume before each dose. Take oral therapy with food and the required liquid; follow exact swallowing or capsule-sprinkling instructions. Do not add potassium supplements, potassium salt substitutes, or NSAIDs without review. Report weakness, palpitations, severe abdominal pain, distention, vomiting, black stool, or blood in stool immediately.

Obtain emergency medical assessment for excess potassium or a suspected infusion error; hyperkalemia may be symptom-free until a dangerous arrhythmia. Stop an implicated IV infusion and initiate urgent ECG/laboratory assessment with clinician-directed treatment. Home remedies are unsafe; management may require potassium-shifting or removal therapy, including dialysis, according to the patient’s condition.

Selected product

Klor-Con 10 mEq wax-matrix ER tablet · Upsher-Smith

Appearance

Yellow, round tablet

Imprint

KC 10

Example NDC

0245-5316-11 · bottle of 100

Selected Klor-Con tablets contain 8 mEq (600 mg KCl) or 10 mEq (750 mg KCl). Selected capsules contain 8 or 10 mEq. Oral solution: 10% = 20 mEq/15 mL; 20% = 40 mEq/15 mL; the selected solution is supplied as institutional-use unit-dose cups. Hospira concentrate: 2 mEq/mL in 10/20/40 mEq single-dose vials, requiring dilution. Baxter ready-to-use bags: 10 mEq/100 mL, 10 mEq/50 mL, 20 mEq/100 mL, 20 mEq/50 mL, or 40 mEq/100 mL. Bag total mEq and concentration mEq/L are different quantities.

Selected oral tablets/capsules: 20–25°C in tight containers; use a child-resistant closure for tablets; tablets permit 15–30°C excursions. Oral solution: 20–25°C, excursions 15–30°C, tight light-resistant container, protect from freezing. Store selected concentrate at 20–25°C; single-dose vials require discard of unused contents. Baxter bags: room temperature 25°C, avoid excessive heat, keep in moisture-barrier overwrap until use. Inspect IV solutions and seals, discard leaking/damaged containers, do not connect bags in series or add supplementary medication to the selected ready-to-use bags.